New drug treats West Nile virus in mice

Mon Aug 4, 2008 5:22pm EDT
 
[-] Text [+]

NEW YORK (Reuters Health) - Continuous administration of a drug dubbed AMD3100 improves survival of mice infected with West Nile virus, scientists at Washington University School of Medicine have found.

The drug allows T cells of the immune system to cross the blood-brain barrier to combat the virus infecting the brain, Dr. Robyn S. Klein and associates explain in their report in the Proceedings of the National Academy of Sciences.

The St. Louis-based team found that, compared with placebo treatment, AMD3100 improved survival in mice infected with West Nile virus by 50 percent.

After 8 days of treatment, AMD3100-treated mice showed a 1000-fold decrease in infectious virus within the brain.

The researchers conclude that manipulation of the immune response in this way "can promote an early increase in immune cell trafficking that controls viral infection, ultimately leading to a rapid dampening of inflammation that can have pathologic consequences."

SOURCE: Proceedings of the National Academy of Sciences, online August 4, 2008.

 
Dr. Qurrath U. Ain of the Elmhurst Pediatric Emergency Center examines a patient with flu-like symptoms at Elmhurst Hospital in New York in this December 12, 2003. file photo. REUTERS/Shannon Stapleton/Files
Healthcare Reform

Reuters provides an in-depth look at the issues facing Americans as the Obama administration wrestles with healthcare policy.  Full Coverage 

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
Uninsured patient Josefa Martinez, 8, has her blood pressure measured during a health check-up at Venice Family Clinic in Venice, California, June 25, 2009.  REUTERS/Lucy Nicholson
The healthcare disconnect

A successful reform package will have to address the cost for services for private versus public providers and employ innovative technological advances, writes Darrell West, author of Digital Medicine: Health Care in the Internet Era.  Commentary | Full Coverage 

Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better